An unnatural biopolymer
CY Cho, EJ Moran, SR Cherry, JC Stephans… - Science, 1993 - science.org
A highly efficient method has been developed for the solid-phase synthesis of an "unnatural
biopolymer" consisting of chiral aminocarbonate monomers linked via a carbamate …
biopolymer" consisting of chiral aminocarbonate monomers linked via a carbamate …
Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance
…, SJ Romano, C Zhang, S Krane, EJ Moran… - Cancer research, 2000 - AACR
OC144-093 is a novel substituted diarylimidazole(M r 495) generated using the OntoBLOCK
system, a solid-phase combinatorial chemistry technology, in combination with high-…
system, a solid-phase combinatorial chemistry technology, in combination with high-…
Radio frequency tag encoded combinatorial library method for the discovery of tripeptide-substituted cinnamic acid inhibitors of the protein tyrosine phosphatase …
EJ Moran, S Sarshar, JF Cargill… - Journal of the …, 1995 - ACS Publications
The introduction of chemicaltagging methods in combina-torial library split synthesis has
enabled the preparation of a number of small molecule libraries. 5 However, tagging strategies …
enabled the preparation of a number of small molecule libraries. 5 However, tagging strategies …
Synthesis of tetrasubstituted imidazoles via α-(N-acyl-N-alkylamino)-β-ketoamides on Wang resin
C Zhang, EJ Moran, TF Woiwode, KM Short… - Tetrahedron letters, 1996 - Elsevier
PII: 0040-4039(95)02310-0 Page 1 Pergamon 0040-4039(95)02310-0 Tetrahedron Letters,
Vol. 37, No. 6, pp, 751-754, 1996 Copyright © 1996 Elsevier Science Lid Printed in Great …
Vol. 37, No. 6, pp, 751-754, 1996 Copyright © 1996 Elsevier Science Lid Printed in Great …
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
…, V Moskalenko, R Lord, EJ Moran… - European …, 2021 - Eur Respiratory Soc
Severe coronavirus disease 2019 (COVID-19) is characterised by pneumonia with excessive
systemic inflammation, referred to as a “cytokine storm” [1–3]. Dexamethasone treatment …
systemic inflammation, referred to as a “cytokine storm” [1–3]. Dexamethasone treatment …
Exploring the positional attachment of glycopeptide/β-lactam heterodimers
…, MS Linsell, DG Marquess, EJ Moran… - The Journal of …, 2008 - nature.com
Further investigations towards novel glycopeptide/β-lactam heterodimers are reported.
Employing a multivalent approach to drug discovery, vancomycin and cephalosporin synthons, 4, …
Employing a multivalent approach to drug discovery, vancomycin and cephalosporin synthons, 4, …
[HTML][HTML] Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive …
…, CN Barnes, W Yates, DL Bourdet, EJ Moran… - Pulmonary …, 2018 - Elsevier
Background Revefenacin (TD-4208) is a potent, lung-selective, long-acting muscarinic
antagonist currently in development as a once-daily nebulized therapy for chronic obstructive …
antagonist currently in development as a once-daily nebulized therapy for chronic obstructive …
A multivalent approach to drug discovery for novel antibiotics
…, K Kaniga, KM Krause, MS Linsell, EJ Moran… - The Journal of …, 2008 - nature.com
The design, synthesis and antibacterial activity of novel glycopeptide/β-lactam heterodimers
is reported. Employing a multivalent approach to drug discovery, vancomycin and …
is reported. Employing a multivalent approach to drug discovery, vancomycin and …
[HTML][HTML] Improvements in lung function with nebulized revefenacin in the treatment of patients with moderate to very severe COPD: results from two replicate phase III …
…, KK Pudi, CN Barnes, EJ Moran… - … Diseases: Journal of …, 2019 - ncbi.nlm.nih.gov
Background: Revefenacin, a novel, lung-selective, long-acting muscarinic antagonist, has
been developed for nebulized therapy for chronic obstructive pulmonary disease (COPD). We …
been developed for nebulized therapy for chronic obstructive pulmonary disease (COPD). We …
[HTML][HTML] Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate
DA Mahler, JA Ohar, CN Barnes, EJ Moran… - … Diseases: Journal of …, 2019 - ncbi.nlm.nih.gov
Background: Patients with chronic obstructive pulmonary disease (COPD) and suboptimal
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …